Ranjzad Fariba, Tara Ahmad, Basiri Abbas, Aghdami Nasser, Moghadasali Reza
Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran-1666677951, Islamic Republic of Iran.
Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran-8158968433, Islamic Republic of Iran.
Exp Ther Med. 2019 Aug;18(2):1345-1349. doi: 10.3892/etm.2019.7693. Epub 2019 Jun 19.
Autosomal dominant polycystic kidney disease (ADPKD) is the fourth most common cause of end-stage renal disease, occurring at a frequency of 1 in 400 to 1 in 800 individuals among different populations. The disease affects all ethnic groups worldwide, and there is a requirement for population-based studies to be conducted in order to improve diagnosis, genetic counseling and treatment. A large Iranian family with ADPKD was recruited for the current study. Clinical evaluation was performed to diagnose and assess disease progression in 11 members of this family, including 7 affected members and 4 unaffected members. and genes were genotyped in subjects by next-generation sequencing (NGS). Mutational analysis of and genes in this family revealed three intronic variations and three synonymous exonic variants in the gene, and two non-synonymous exonic variants and eight intronic variants in , resulting in a total of 16 heterozygous variations among these two genes. Among the 16 variations, all except three intronic variants in the gene have already reported in the Iranian population. The three novel mutations were predicted to be deleterious polymorphisms using methods. Among the reported intronic variations, rs201204878 was identified as a splice region variant, leading to truncation of the polycystin-1 protein. In conclusion, genotyping of and in this family with ADPKD revealed no mutational hot spots. However, genetic screening identified three novel variants in the Iranian population. The data generated in the present study will contribute to improving the diagnosis, genetic counseling and treatment of patients with ADPKD.
常染色体显性多囊肾病(ADPKD)是终末期肾病的第四大常见病因,在不同人群中的发病率为400分之一至800分之一。该疾病影响全球所有种族,因此需要开展基于人群的研究以改善诊断、遗传咨询和治疗。本研究招募了一个患有ADPKD的大型伊朗家族。对该家族的11名成员进行了临床评估,以诊断和评估疾病进展,其中包括7名患病成员和4名未患病成员。通过下一代测序(NGS)对受试者的PKD1和PKD2基因进行基因分型。对该家族PKD1和PKD2基因的突变分析显示,PKD1基因有3个内含子变异和3个同义外显子变异,PKD2基因有2个非同义外显子变异和8个内含子变异,这两个基因共有16个杂合变异。在这16个变异中,除PKD1基因的3个内含子变异外,其他变异均已在伊朗人群中报道。使用SIFT方法预测这3个新突变是有害多态性。在已报道的内含子变异中,rs201204878被鉴定为剪接区域变异,导致多囊蛋白-1蛋白截短。总之,对这个ADPKD家族的PKD1和PKD2基因分型未发现突变热点。然而,基因筛查在伊朗人群中发现了3个新变异。本研究产生的数据将有助于改善ADPKD患者的诊断、遗传咨询和治疗。